What factors correlate with a better response to BCMA-directed CAR T-cell products?

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub was pleased to speak to Nina Shah, UCSF, San Francisco, US. We asked, What factors correlate with a better response to BCMA-directed CAR T-cell products?

In this video, Shah discusses how data from the KarMMa trial can be used to try to establish a correlation between clinical and drug product characteristics, and patients achieving a complete response. Shah then talks about the importance of determining what patients are more likely to achieve a complete response, so CAR T-cell therapy can be given appropriately to patients.